Comparison of other genetic alterations between AML patients with and without the IDH1 mutation
| Variant . | Percentage of patients with the gene mutation . | P . | ||
|---|---|---|---|---|
| Total patients (n = 493) . | IDH1-mutated patients (n = 27) . | IDH1 wild-type patients (n = 466) . | ||
| NPM1 | 21.4 (105/493) | 55.6 (15/27) | 19.4 (90/466) | < .001 |
| CEBPA | 13.2 (65/493) | 3.7 (1/27)) | 13.8 (64/466) | .134 |
| FLT3/ITD | 23.4 (115/493) | 37.0 (10/27) | 22.6 (105/466) | .083 |
| RUNX1 | 12.2 (60/493) | 7.4 (2/27) | 12.4 (58/466) | .436 |
| WT1 | 6.3 (31/493) | 0 (0/27) | 6.7 (31/466) | .166 |
| MLL/PTD | 5.7 (28/493) | 11.1 (3/27) | 5.4 (25/466) | .210 |
| FLT3/D835 | 7.5 (37/493) | 11.1 (3/27) | 7.3 (34/466) | .465 |
| KIT | 2.4 (12/493) | 0 (0/27) | 2.6 (12/466) | .398 |
| JAK2 | 0.6 (3/493) | 0 (0/27) | 0.6 (3/466) | .676 |
| PTPN11 | 4.1 (20/493) | 7.4 (2/27) | 3.9 (18/466) | .364 |
| NRAS | 11.5 (57/493) | 14.8 (4/27) | 11.4 (53/466) | .586 |
| KRAS | 3.3 (16/493) | 0 (0/27) | 3.4 (16/466) | .328 |
| Variant . | Percentage of patients with the gene mutation . | P . | ||
|---|---|---|---|---|
| Total patients (n = 493) . | IDH1-mutated patients (n = 27) . | IDH1 wild-type patients (n = 466) . | ||
| NPM1 | 21.4 (105/493) | 55.6 (15/27) | 19.4 (90/466) | < .001 |
| CEBPA | 13.2 (65/493) | 3.7 (1/27)) | 13.8 (64/466) | .134 |
| FLT3/ITD | 23.4 (115/493) | 37.0 (10/27) | 22.6 (105/466) | .083 |
| RUNX1 | 12.2 (60/493) | 7.4 (2/27) | 12.4 (58/466) | .436 |
| WT1 | 6.3 (31/493) | 0 (0/27) | 6.7 (31/466) | .166 |
| MLL/PTD | 5.7 (28/493) | 11.1 (3/27) | 5.4 (25/466) | .210 |
| FLT3/D835 | 7.5 (37/493) | 11.1 (3/27) | 7.3 (34/466) | .465 |
| KIT | 2.4 (12/493) | 0 (0/27) | 2.6 (12/466) | .398 |
| JAK2 | 0.6 (3/493) | 0 (0/27) | 0.6 (3/466) | .676 |
| PTPN11 | 4.1 (20/493) | 7.4 (2/27) | 3.9 (18/466) | .364 |
| NRAS | 11.5 (57/493) | 14.8 (4/27) | 11.4 (53/466) | .586 |
| KRAS | 3.3 (16/493) | 0 (0/27) | 3.4 (16/466) | .328 |